



NDA 18-735/SLR-044
NDA 20-327/SLR-002

Bracca Diagnostics Inc.
Attention: Melanie Benson
Director, US Regulatory Affairs
P.O. Box 5225
Princeton, NJ 08543-5225

Dear Ms. Benson:

Please refer to your supplemental new drug applications dated April 30, 1999 (May 5, 1999 on FDA 356h form), received May 11, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Isovue®(iopamidol injection) and Isovue Multipack® (iopamidol injection-pharmacy bulk pack).

This supplemental new drug application provides for the addition of "temporary cortical blindness" and "temporary amnesia" to the ADVERSE REACTIONS section of the package inserts.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon draft marked up labeling. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package inserts submitted May 5, 1999).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 18-735/SLR-044 and NDA 20-327/SLR-002." Approval of this submission by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

NDA 18-735/SLR-044

NDA 20-327/SLR-002

Page 2

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Patricia A. Stewart, Project Manager, at (301) 827-7510.

Sincerely,

{See appended electronic signature page}

Patricia Y. Love, M.D., M.B.A.
Director
Division of Medical Imaging and Radiopharmaceutical
Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Patricia Love
7/8/02 12:11:35 PM